Volume 22, Number 3—March 2016
Dispatch
Signs or Symptoms of Acute HIV Infection in a Cohort Undergoing Community-Based Screening
Table 2
Characteristic |
Signs/symptoms |
p value |
Signs/symptoms |
p value |
|||
---|---|---|---|---|---|---|---|
Compatible with AHI† |
Resolved before NAT |
Ongoing at NAT |
Persons seeking medical attention |
Persons not seeking medical attention |
|||
No. persons reporting symptoms | 69 | 16 | 41 | 10 | 22 | ||
Duration of symptoms, d, median (IQR) | 8 (5–11) | 7 (4–8) | 11 (7–13) | <0.01 | 13 (10–17) | 10 (4–11) | 0.01 |
No. (%) persons with typical AHI |
64 (93) |
15 (94) |
36 (86) |
NS |
10 (100) |
18 (82) |
NS |
Signs or symptoms, no. (%) | |||||||
Fever | 53 (77) | 11 (69) | 34 (83) | NS | 9 (90) | 16 (73) | NS |
Myalgia | 48 (70) | 13 (81) | 28 (68) | NS | 8 (80) | 12 (55) | NS |
Fatigue | 48 (70) | 13(81) | 29 (71) | NS | 9 (90) | 13 (59) | NS |
Headache | 42 (61) | 10 (63) | 27 (66) | NS | 8 (80) | 11 (50) | NS |
Night sweats | 38 (55) | 5 (31) | 26 (63) | 0.04 | 7 (70) | 9 (41) | NS |
Pharyngitis | 34 (49) | 9 (56) | 17 (41) | NS | 4 (40) | 11 (50) | NS |
GI symptoms‡ | 29 (42) | 3 (19) | 22 (54) | 0.02 | 5 (50) | 7 (32) | NS |
Rash | 19 (28) | 6 (38) | 12 (29) | NS | 5 (50) | 5 (23) | NS |
Weight loss§ | 15 (22) | 2 (13) | 12 (29) | NS | 6 (60) | 3 (14) | 0.01 |
Arthralgia | 14 (20) | 3 (19) | 8 (20) | NS | 4 (40) | 1 (5) | 0.02 |
*AHI, acute HIV infection; GI, gastrointestinal; IQR, interquartile range; NAT, nucleic acid amplification testing; NS, not significant.
†Defined as having started <4 days before estimated date of infection or after the estimated date of infection.
‡General GI symptoms (e.g., nausea, vomiting, and diarrhea).
§Weight loss >2.5 kg.
Page created: February 18, 2016
Page updated: February 18, 2016
Page reviewed: February 18, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.